APTEVO THERAPEUTICS INC. — Income Charts
32 quarters of history · ending 2022-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-100.0% -$4M
$0
Cost of Revenue↑+37.5% +$2M
$6M
R&D↑+2.9% +$131K
$5M
SG&A↓-24.1% -$2M
$5M
D&A↓-37.1% -$95K
$161K
Operating Income↓-63.9% -$3M
$-8M
EBITDA↓-37.1% -$95K
$161K
Other Income/Expense↓-12.3% -$77K
$-702K
Pretax Income
$14M
Tax Provision
$-999K
Net Income↓-9.2% -$647K
$-8M
Operating Margin↑+104.3pts
-180.2%
Net Margin↑+52.5pts
-247.2%
Effective Tax Rate
8.3%
Deferred Tax Liabilities
$15M
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-0.8pts
-1.8%
ETR Foreign Differential (pp)
—
Operating Lease Cost↓-19.4% -$72K
$299K
Revenue YoY Variation↓-154.4pts
-100.0%
Income YoY Variation↓-87.8pts
-63.9%
Revenue QoQ Variation↓-128.5pts
-100.0%
Income QoQ Variation↓-19.9pts
-2.9%